REVIEW type 1 diabetes and autoimmune polyglandular syndrome: a clinical review A. Van den Driessche, V. Eenkhoorn, L. Van Gaal, C. De Block* Department of Diabetology and Endocrinology, Antwerp University Hospital, Edegem, Belgium, *corresponding author: tel.: 32-3-821 32 78, fax: 32-3-825 49 80, e-mail:
[email protected] abstraCt Keywords type 1 diabetes mellitus (t1dM) results from autoimmune Autoantibodies, autoimmune polyglandular syndrome, destruction of insulin-producing β cells and is characterised type 1 diabetes mellitus by the presence of insulitis and β-cell autoantibodies. up to one third of patients develop an autoimmune polyglandular syndrome. fifteen to 30% of t1dM subjects introduCtion have autoimmune thyroid disease (hashimoto’s or graves’ disease), 5 to 10% are diagnosed with autoimmune gastritis Type 1 diabetes mellitus (T1DM), arising through a complex and/or pernicious anaemia (AIG/PA), 4 to 9% present interaction of immune, genetic and environmental factors, with coeliac disease (Cd), 0.5% have addison’s disease results from autoimmune destruction of insulin-producing (AD), and 2 to 10% show vitiligo. these diseases are β cells. T1DM is characterised by the appearance of characterised by the presence of autoantibodies against insulitis and the presence of β-cell autoantibodies.1 In up to thyroid peroxidase (for hashimoto’s thyroiditis), TSH one third of patients the autoimmune attack is not limited receptor (for graves’ disease), parietal cell or intrinsic to β cells, but expands into an autoimmune polyglandular factor (for AIG/PA), tissue transglutaminase (for Cd), syndrome.2-8 Of type 1 diabetic subjects, 15 to 30% have and 21-hydroxylase (for AD).